Drugs /

infigratinib

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

NCI Definition [1]:
An orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for infigratinib

Infigratinib has been investigated in 9 clinical trials, of which 8 are open and 1 is closed. Of the trials investigating infigratinib, 1 is early phase 1 (1 open), 4 are phase 1 (3 open), 2 are phase 2 (2 open), and 2 are phase 3 (2 open).

FGFR2 Fusion, FGFR2 Mutation, and FGFR3 Fusion are the most frequent biomarker inclusion criteria for infigratinib clinical trials.

Cholangiocarcinoma, breast carcinoma, and malignant solid tumor are the most common diseases being investigated in infigratinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Infigratinib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Infigratinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating infigratinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea, bgj398, bgj-398
Drug Categories [2]:
FGFR1/2/3 inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
FGFR1, FGFR2, FGFR3, FGFR4
NCIT ID [1]:
C88302

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.